人工智能驱动基于形态学富集体液中的恶性细胞
本研究应用Deepcell平台结合微流控分选、明场成像和基于多维形态的实时深度学习,从恶性积液中富集癌细胞而无需染色或标记。全基因组测序和靶向突变分析验证了富集效果,对初始低水平或不可检测的肿瘤组分和关键体细胞突变检测灵敏度更高。研究证明在传统形态学细胞学中补充深度学习、多维形态分析和微流控分选具有可行性和附加价值。
要点
- Deepcell平台可无标记富集恶性积液中的癌细胞
- 富集后测序检测肿瘤组分和关键突变的灵敏度提高
- 深度学习联合微流控分选可增强传统细胞学的分子分析能力
核心结论
- 深度学习驱动的多维形态分析与微流控分选联用可从恶性积液中无标记富集癌细胞,并提高下游分子检测灵敏度。
研究设计与样本
- 应用Deepcell平台(整合微流控分选、明场成像和实时深度学习)从恶性积液中富集癌细胞,并用全基因组测序和靶向突变分析验证。
主要发现
- 富集后对肿瘤组分的检测灵敏度高于分选前患者样本。
- 富集后对初始低水平或不可检测的关键体细胞变异突变检测灵敏度提高。
临床怎么用
- 在传统形态学细胞学基础上补充深度学习多维形态分析和微流控分选,可能提升恶性积液下游分子检测的成功率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cell morphology is a fundamental feature used to evaluate patient specimens in pathologic analysis. However, traditional cytopathology analysis of patient effusion samples is limited by low tumor cell abundance coupled with the high background of nonmalignant cells, restricting the ability of downstream molecular and functional analyses to identify actionable therapeutic targets. We applied the Deepcell platform that combines microfluidic sorting, brightfield imaging, and real-time deep learning interpretations based on multidimensional morphology to enrich carcinoma cells from malignant effusions without cell staining or labels. Carcinoma cell enrichment was validated with whole genome sequencing and targeted mutation analysis, which showed a higher sensitivity for detection of tumor fractions and critical somatic variant mutations that were initially at low levels or undetectable in presort patient samples. Our study demonstrates the feasibility and added value of supplementing traditional morphology-based cytology with deep learning, multidimensional morphology analysis, and microfluidic sorting.
引用
- Mavropoulos A, Johnson C, Lu V, et al. Artificial Intelligence-Driven Morphology-Based Enrichment of Malignant Cells from Body Fluid. Mod Pathol. 2023. PMID: 37100228. doi:10.1016/j.modpat.2023.100195
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。